Leading gene and cell therapy group, Oxford Biomedica, has signed a new three year Master Services & Development Agreement with AstraZeneca UK which would facilitate potential future manufacturing opportunities for the AstraZeneca COVID-19 vaccine. This represents an expansion of the original Master Supply and Development Agreement announced between the two companies in September 2020.
The manufacture of COVID-19 vaccines at Oxford Biomedica’s Oxbox facility in the city of Oxford is expected to complete in the last quarter of 2022, as part of the original commitment. In accordance with the terms of the original agreement and inclusive of revenues for batches already manufactured in the first half of 2022, Oxford Biomedica expects to recognise aggregate revenues of approximately £30 million from AstraZeneca in the current financial year.
Under the new agreement, manufacturing of vaccines at Oxford Biomedica’s world class 84,000 sq. ft manufacturing facility, Oxbox, will be available to AstraZeneca on an as needed basis beyond 2022.
Dr Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: “I am delighted that our close partnership with AstraZeneca has been extended. I am proud of the work of all our colleagues at Oxford Biomedica that has enabled us to deliver more than 100 million doses of lifesaving COVID-19 vaccine. While contributing to the efforts to fight the pandemic, this has also demonstrated Oxford Biomedica’s ability to expand the scope of our innovative process development services and deliver high-performing manufacturing solutions beyond lentiviral vectors. We look forward to continuing to work closely with AstraZeneca and execute on our strategy to become a global leader across all viral vectors, enabling Cell and Gene Therapy companies to deliver their life-changing therapies to patients.”